 The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone given orally at a dose of 40 mg per day for 4 days, rituximab given intravenously at a dose of 500mg once, cyclosporin given orally at a dose of 2.5-3 mgkg per day for 28 days and intravenous immunoglobulin given intravenously at a dose of 5g per month for 6 months for the treatment of adults newly diagnosed ITP patients. 